Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Kane Biotech Inc V.KNE

Alternate Symbol(s):  KNBIF

Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired from research institutions. DispersinB, coactiv+, coactiv+, DermaKB, DermaKB Biofilm, and revive are trademarks of the Company. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. In Wound Care & Surgical applications, in addition to revyve Antimicrobial Wound Gel, it is developing follow-on products with three applications: coactiv+ Antimicrobial Surgical Hydrogel, coactiv+ Antimicrobial Wound Gel Spray, and coactiv+ Antimicrobial Wound Rinse. The Company's other biofilm disruption technology is DispersinB.


TSXV:KNE - Post by User

Post by StoneMan45on Feb 18, 2021 10:43am
156 Views
Post# 32595252

KANE ROCKS

KANE ROCKSthe deal with Animalcare  Group in creating STEM is a big deal and that site should be fully functional soon but the wound care deal will be huge. 


https://d1io3yog0oux5.cloudfront.net/_ba75517359a0ec7ac71075819872de0b/kanebiotech/db/447/3370/pdf/2736-KAN-Investor+Presentation+Dec+2020+.pdf

Kane Wound Care and Surgical (KWCS) • Significant progress has been made towards creating Kane’s Wound Care Commercialization Vehicle at a valuation 4 to 5 times Kane’s current Market Cap. • Financing – over $7M in non-dilutive financing obtained and $6M available




Commercialization vehicle target Q2 2021 • $70M valuation estimated based on Strategic Partner investment • First commercial sale target Q1 2022

Advanced discussions with multiple potential partners – $7M equity investment – 9.9% equity stake in KWCS – Exclusive US rights to current and future Kane technology and products – Products to be purchased by strategic partner from KWCS and resold through existing sales network
<< Previous
Bullboard Posts
Next >>